ALEXANDRIA, Va., June 17 -- United States Patent no. 12,312,588, issued on May 27, was assigned to Duke University (Durham, N.C.).

"Nucleolin-targeting aptamers and methods of using the same" was invented by Bruce A. Sullenger (Durham, N.C.), Michael Goldstein (Durham, N.C.), Elizabeth D. Pratico (Durham, N.C.), Michael Kastan (Durham, N.C.) and Bethany Gray (Durham, N.C.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are compositions including aptamers capable of binding to and/or inhibiting the activity of nucleolin. Methods of treating cancer in a subject by administering such compositions are also provided."

The patent was filed on June 2, 2023, under Application No. 18/205,390.

*For fu...